DUBLIN--(BUSINESS WIRE)--The "Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Uterine Leiomyoma (Uterine Fibroids) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Uterine Leiomyoma (Uterine Fibroids) Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Uterine Leiomyoma (Uterine Fibroids)
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
Companies Mentioned
- AbbVie Inc
- Addex Therapeutics Ltd
- Bayer AG
- BioSpecifics Technologies Corp
- Dongkook Pharmaceutical Co Ltd
- Kissei Pharmaceutical Co Ltd
- Laboratoire HRA Pharma
- Ogeda SA
- Repros Therapeutics Inc
- Takeda Pharmaceutical Company Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4vndsd/uterine_leiomyoma?w=4
